ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Siegfried Transfers A Plant To Celgene

by Rick Mullin
July 20, 2015 | APPEARED IN VOLUME 93, ISSUE 29

Swiss fine chemicals maker Siegfried has sold a production building at its facility in Zofingen, Switzerland, to the biotech firm Celgene. The agreement builds on a contract signed 10 years ago under which Celgene has exclusive rights to capacity in Zofingen for production of the active ingredient in its multiple myeloma drug Revlimid. Separately, German and French authorities have green-lighted Siegfried’s acquisition, announced earlier this year, of three European custom synthesis sites from BASF.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment